Trial-by-gene · BRCA1/2 (and HRR)
Active clinical trials enrolling BRCA-mutant metastatic prostate
Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.
BRCA-mutant mCRPC trials focus on (1) PARP + AR-targeted combinations earlier in the disease course, (2) PARP-resistance mechanisms and combinations to overcome reversion mutations, (3) earlier-line trials in metastatic hormone-sensitive prostate cancer (mHSPC), and (4) novel combinations (ATR inhibitors, ATM inhibitors, immunotherapy combinations).
See the BRCA2 prostate cheat sheet for the evidence base.
Browse the live listing
Search ClinicalTrials.gov for actively recruiting prostate cancer trials with BRCA / HRR-directed interventions.
Open ClinicalTrials.gov listingSource: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.
Representative trial phases and designs
Phase III, 1L mCRPC
PROpel, TALAPRO-2, MAGNITUDE — established 1L PARP + AR-targeted combinations.
Phase II, post-PARP resistance
ATR inhibitor combinations after PARP progression.
Phase III, mHSPC
PARP combinations in metastatic hormone-sensitive prostate cancer, earlier than current standards.
Frequently asked questions
- Are non-BRCA HRR-mutant patients eligible?
- Many trials accept BRCA1/2 + additional HRR genes (ATM, CHEK2, PALB2, etc.) with stratification. BRCA2 typically shows the strongest treatment effect; ATM weaker.